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Background: The Pneumonia Severity Index (PSI) and CRB-65 are scores used to predict
mortality in patients with community-acquired pneumonia (CAP). It is unknown how well
either score predicts time to clinical stability in hospitalized patients with CAP. Thus, it is also
not known which score predicts time to clinical stability better.
Methods: A secondary analysis of 3087 patients from the Community-Acquired Pneumonia
Organization (CAPO) database was performed. Time-dependent receiver-operator character-
istic (ROC) curves for time to clinical stability were calculated for the PSI and CRB-65 scores
at day seven of hospitalization. Secondary outcomes were to assess the relationship of the
PSI and CRB-65 to in-hospital mortality and length of stay (LOS). ROC curves for LOS and
mortality were calculated.
Results: The area under the ROC curve (AUC) for time to clinical stability by day seven was
0.638 (95% CI 0.613, 0.660) when using the PSI, and 0.647 (95% CI 0.619, 0.670) while using2)852 1148; fax: þ1 (502) 852 1147.
.edu (F.W. Arnold).
0 Elsevier Ltd. All rights reserved.
Pneumonia score predictive accuracy for time to stability 1737the CRB-65. The difference in AUC values was not statistically significant (95% CI for difference
of 0.03 to 0.01). However, the difference in the AUC values for discharge within 14 days
(0.651 for PSI vs 0.63 for CRB-65, 95% CI for difference 0.001e0.049), and 28-day in-hospital
mortality (0.738 for PSI vs 0.69 for CRB-65, 95% CI for difference 0.02e0.082) were both statis-
tically significant.
Conclusions: This study demonstrates a moderate ability of both the PSI and CRB-65 scores to
predict time to clinical stability, and found that the predictive accuracy of the PSI was equiv-
alent to that of the CRB-65 for this outcome.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Over a million patients are hospitalized each year for
community-acquired pneumonia (CAP) in the United
States.1 After decades of research and patient care,
pneumonia has remained one of the top ten causes of death
(currently eighth) in the United States.2 Because of the
diversity of care among physicians caring for patients with
CAP, and the high rate of mortality among patients with
CAP, there is a need for an accurate predictive tool to make
appropriate management clear to physicians.3,4 The widely
endorsed pneumonia severity index (PSI) was originally
described in 1997, followed by the British Thoracic Society
score; CURB in 2001 and CRB-65 in 2004.5,6 A significant
relationship between each score and mortality has been
verified.7e10 Which score is the most useful has not been
settled.
Evaluating a different outcome than mortality may be
more useful to determine the better score as the US Food
and Drug Administration designated time to clinical
stability to be a relevant outcome to study CAP.11 However,
only two studies, to our knowledge, address how well the
PSI predicts time to clinical stability,12,13 and no study
evaluates how well the CRB-65 predicts time to clinical
stability. Thus no study compares the predictive ability of
the two scores.14,15
If one score was known to have a higher predictive
accuracy for time to clinical stability, then it would serve as
evidence for clinicians to use that particular score to help
guide decisions about switch therapy from intravenous to
oral antimicrobial therapy, and decisions about hospital
discharge. Researchers could compare times to clinical
stability in patients receiving different antibiotic regimens
to determine which one is better. On the other hand, if the
two scores were known to have the same predictive accu-
racy for time to clinical stability, then it would provide
evidence for the current Infectious Diseases Society of
America (IDSA)/American Thoracic Society (ATS) guidelines
for CAP, which recommend using either score.
In order to allow a comparison of populations with CAP,
and because the PSI and the CRB-65 scores have widespread
adoption, knowing how well each score predicts short term
outcomes based on patient characteristics at the time of
hospitalization is needed. The present study sought to
define and compare how well the PSI and the CRB-65
predicts time to clinical stability in hospitalized patients
with CAP. Secondary outcomes were to assess the rela-
tionship of the PSI and CRB-65 to mortality and length of
stay (LOS).Materials and methods
Study design and population
This was an international, retrospective, observational
study in which a secondary analysis was performed of the
Community-Acquired Pneumonia Organization (CAPO)
database including hospitalized patients 18 years of age.
Data from June 10, 2001 until November 10, 2006 were
collected from 41 hospitals in 12 countries (see appendix).
The process of how the database was assembled and used
was described previously.16 Local institution review board
(IRB) permission was requested, and consent was waived
because this study was retrospective and observational. In
each participating center primary investigators selected
one or more patients from a list of hospitalized patients
with a diagnosis of CAP. Severity of disease data was
collected, as well as, patient demographics, culture results
and appropriateness of antimicrobial therapy for patients in
whom a pathogen was identified.Study definitions
CAP was defined as a new pulmonary infiltrate (within 24 h
of admission), and associated with at least one of the
following factors: a new or increased cough, an abnormal
temperature (<35.8 C or >37.8 C), or an abnormal
leukocyte count (leukocytosis, leucopenia or the absence
of immature neutrophils). Pneumonia was considered as
community-acquired if a patient had no history of hospi-
talization during the two weeks prior to admission.
The PSI and CRB-65 were calculated for each patient as
described previously, except confusion was determined by
noting pertinent documentation in the medical record
regarding new disorientation to person, place or time
rather than by knowing the Abbreviated Mental Test
Score.5,17 There are five possible rankings for each pneu-
monia severity score (highest is most severe). Possible PSI
risk classes range from I to V, and possible CRB-65 scores
range from zero to four.
Time to clinical stability was defined using the ATS
criteria for switch therapy from intravenous to oral anti-
biotic therapy: 1) improvement in cough and shortness of
breath; 2) afebrile status for 8 h (<37.8 C); 3) normal-
izing leukocyte count by at least 10% from the previous day;
and 4) adequate oral intake.18 The first day of hospitali-
zation was day zero. Time to clinical stability was calcu-
lated in days as the day that the above four criteria were
Table 1 Demographics of hospitalized patients with
community-acquired pneumonia.
No. patients (%)
Total n Z 3085 (100)
Mean age (years) 65.8
PSI and CRB-65 variables
Male 1909 (62)
Nursing home resident 178 (6)
Neoplastic disease 300 (10)
Liver disease 126 (4)
Congestive heart failure 627 (20.3)
Cerebrovascular disease 478 (16)
Renal disease 349 (11)
Altered mental status 399 (13)
Respiratory rate 30 breaths/min 675 (22)
Systolic blood pressure <90 mmHg 167 (5)
Temperature <35 C or 40 C 179 (6)
Heart rate 125 beats/min 391 (13)
pH <7.35 185 (6)
BUN >30 mg/dL 644 (21)
Sodium <130 mmol/L 195 (6)
Glucose >250 mg/dL 198 (6)
Hematocrit <30% 207 (7)
PaO2 <60 mmHg 1161 (38)
Pleural effusion 554 (18)
Other comorbidities
Chronic obstructive pulmonary disease 890 (29)
Diabetes mellitus 588 (19)
1738 F.W. Arnold et al.filled simultaneously minus the admission date. Information
on criteria for clinical stability was collected for the first
seven days following diagnosis or until the four criteria
were met. Length of stay was calculated as the discharge
date minus the admission date. Mortality was assessed as
28-day in-hospital mortality.
Statistical methods
All patients who did not meet criteria for clinical stability
within seven days were considered right censored at day
seven. Patients remaining in the hospital longer than 30
days were right censored at 30 days. Cumulative incidence
curves19 were estimated for time to clinical stability, LOS
and mortality, and were stratified by PSI risk class and CRB-
65 severity scores. Proportional hazards regression models
for competing risks were fit to the three outcomes using
the PSI, PSI risk class and CRB-65 as predictors.20 To
properly account for patients who died in the hospital, in-
hospital mortality was treated as a competing risk in the
analysis. Also, hospital discharge was treated as
a competing risk when analyzing in-hospital mortality. The
c2 test statistics21 were used for differences in the three
outcomes between the levels of both severity scores. The
predictive accuracy of the fitted hazard models with the
severity scores were evaluated and compared based on
time-dependent measures of sensitivity, specificity, ROC
curves, and areas underneath the ROC curve (AUC).22
Predictive accuracy was calculated for clinical stability by
day seven, discharge by day 14, and in-hospital mortality
within 28 days. The bootstrap percentile method was used
to calculate 95% confidence intervals (CI) for the time-
dependent AUC measures and difference between
measures.23 All analyses were done using R version 2.8.1,
with package survivalROC used to calculate time-depen-
dent ROC curves and AUC values, the cmprsk package used
for calculation of cumulative incidence curves and
proportional hazards models, and the boot package used
for all bootstrap calculations.22,24,25 An analysis of the
predictive accuracy for time to clinical stability of each
score was performed using two process of care factors:
appropriate antibiotics according to the IDSA/ATS 2007
guidelines for CAP (adherent, under-treated, and over-
treated), and time to first antibiotic dose (whether or not
received within 8 h).
Results
A total of 3085 patients were evaluated for each of the
three outcomes; time to clinical stability, LOS and
mortality. The PSI categorized most patients in risk class IV
(37%), while the CRB-65 score categorized most patients in
score 1 or 2 (59%). A total of 708 patients (23%) had path-
ogens identified with sensitivities. Streptococcus pneumo-
niae was identified in 310 patients, Haemophilus influenza
in 87 patients, Moraxella catarrhalis in 32 patients, atypical
pathogens (Legionella, Mycoplasma and Chlamydia) in 60
patients, methicillin-sensitive Staphylococcus aureus in 52
patients, methicillin-resistant S. aureus in 55 patients, and
Pseudomonas aeruginosa in 47 patients. Fifty-nine of those
patients had a combination of pathogens identified.Demographics of hospitalized patients with community-
acquired pneumonia are in Table 1 along with the
frequency of all of the variables for each of the scores,
including nursing home status. The most common antibiotic
regimens were; a b-lactam plus a macrolide (1099), a fluo-
roquinolone alone (651) and a b-lactam alone (598). A total
of 42% of patients had monotherapy and 46% had combi-
nation therapy (Table 2). Time to first antimicrobial was
somewhat shorter in high risk patients (median 4 hours)
compared to low risk patients (median 5 hours; p < 0.001).
Nearly all patients were unstable at hospital admission
with 94% having a cough and/or shortness of air, 73% having
a fever and 54% not tolerating oral intake. Table 3 gives the
median time and inter-quartile range (IQR e 25th and 75th
percentiles) until each criterion for clinical stability was
met. The overall time to clinical stability was the day all
four criteria were met. Table 4 depicts the median time to
clinical stability, median LOS, and mortality for patients in
each PSI risk class and CRB-65 score. Among the patient
population, 2090 (68%) patients reached clinical stability
within seven days. The relationship between the time to
clinical stability and each of the severity scores (the PSI,
the PSI risk class and the CRB-65) was statistically signifi-
cant (p < 0.001).
Fig. 1 shows the cumulative incidence plots for patients
reaching clinical stability stratified by both the PSI risk
class and CRB-65 scores. Data over time for both scores
shows that as the severity level increases, fewer patients
reach clinical stability by day seven. The range of
Table 2 Empiric antimicrobial regimens provided to
patients with CAP.
Empiric treatment regimen No. (%)
b-Lactam based regimens 1851 (60.0)
b-Lactam alone 598 (19.4)
b-Lactam þ Macrolide 1099 (35.6)
b-Lactam þ othera þ Macrolide 154 (5.0)
Fluoroquinolone  othera 744 (24.1)
b-Lactam þ Fluoroquinolone  othera 244 (7.9)
Macrolide  othera 68 (2.2)
Combination regimens
Fluoroquinolone þ Macrolide 
b-Lactam  othera
180 (5.8)
a “Other” antibiotics with the number of patients who used
each: amikacin (1), aztreonam (1), chloramphenicol (2), clin-
damycin (62), doxycycline (3), gentamicin (13), metronidazole
(28), pentamidine (2), primaquine (1), rifampin (2), trimetho-
prim/sulfamethoxazole (31), vancomycin (43).
Table 3 The time for each criterion to clinical stability,
and the proportion of each criterion stable on the day of
patient admission.
Unstable on
day 0b
Time to clinical stabilitya
Median Inter-quartile
Criterion for
Stability
No. (%) (Days) Range (days)
Improving
symptomsc
2894 (94) 2 3e6
Temperature
<37.8 C
2257 (73) 1 0e3
Improving
leukocytosisd
2459 (80) 2 1e4
Tolerating oral
intakee
1661 (54) 1 0e3
a The time to clinical stability indicates the first day that all
four criteria were stable.
b The day of admission was considered day zero.
c Cough and shortness of breath improving or back to
baseline.
d Improving by at least 10% from previous day.
e Receiving an oral diet or oral medications.
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day seven was more varied with the CRB-65 (83e6% from
score zero to four) than the PSI (87e46% from risk class I to
V) (Table 4). The proportion of patients with CRB-65 scores
of 3 or 4, however, was low (3.5%). Fig. 2 shows the ROC
curves for patients reaching clinical stability within seven
days. The AUC values for the PSI risk class (0.638) and CRB-
65 (0.647) were nearly identical (Table 5), yielding
a difference with a 95% CI that crosses zero (0.03, 0.01).
This indicates that they are equally effective at predicting
which patients will reach clinical stability within seven
days.
The severity scores were also predictive of the LOS and
in-hospital mortality within 28 days. A total of 260 patients
died. The mortality rate ranged from 4.9% to 87.5% for each
score of the CRB-65, while it ranged from 2.6% to 26.5% for
each PSI risk class (Table 4). For LOS, the median value
ranged from 6 to greater than 30 for each CRB-65 score, andTable 4 Time to clinical stability (TCS), length of stay (LOS),
acquired pneumonia according to two severity scores; the pneum
CAP Severity
score
Level No.
patients
No.
deaths
Median
and IQR TCSa
(days)
PSI I 306 8 3 (2, 5)
II 462 8 3 (2, 6)
III 677 25 4 (2, 7)
IV 1130 84 5 (3, >7)
V 510 135 >7 (4, >7)
CRB-65 0 1152 56 3 (2, 6)
1 1298 82 4 (3, >7)
2 527 67 6 (3, >7)
3 92 41 >7 (6, >7)
4 16 14 >7 (>7, >7)
CAP Z Community-Acquired Pneumonia, CI Z confidence interval, IQ
LOS Z Length of Stay, TCS Z Time to Clinical Stability.
a TCS was not right censored at day seven for this table.from 5 to 14 for each PSI risk class. While the range for both
outcomes was greater for the CRB-65, the patients in each
PSI risk class were more evenly distributed. The PSI risk
class had higher overall predictive accuracy for both LOS
(AUC of 0.651 vs 0.626), and mortality (AUC of 0.738 vs
0.69), relative to the CRB-65 score (Table 5). In both cases
the difference was statistically significant, as the confi-
dence intervals for the differences both excluded zero
(0.001e0.049 for LOS, 0.020e0.082 for mortality) (Figs. 3
and 4).
Low risk and high risk patients received similarly overuse
and underuse of antibiotic treatment when a causative
pathogen was identified (47% in risk classes IeIII, 53% in risk
classes IVeV, pZ 0.33). Addition of the two process of careand mortality among hospitalized patients with community-
onia severity index (PSI) and the CRB-65.
Proportion clinically
stable by day seven
(95% CI)
Median and IQR
LOS (days)
Mortality
(95% CI)
87 (83, 91) 5 (3, 9) 2.6 (1, 4)
82 (78, 86) 5 (3, 9) 1.7 (1, 3)
75 (72, 79) 7 (4, 11) 3.7 (2, 5)
69 (66, 71) 8 (5, 15) 7.4 (6, 9)
46 (42, 51) 14 (7, >30) 26.5 (23, 30)
83 (81, 85) 6 (3, 10) 4.9 (4, 6)
68 (66, 71) 7 (5, 14) 6.3 (5, 8)
56 (51, 60) 10 (6, 21) 12.7 (10, 16)
28 (19, 38) 27 (10, >30) 44.6 (34, 54)
6 (0, 27) >30 (>30, >30) 87.5 (53, 97)
R Z inter-quartile range (25th percentile and 75th percentile),
Figure 1 Cumulative incidence plots of hospitalized patients with community-acquired pneumonia reaching clinical stability for
the pneumonia severity index (Fig. 1a) and CRB-65 (Fig. 1b).
Figure 2 ROC curves for hospitalized patients with commu-
nity-acquired pneumonia reaching clinical stability within 7
days for each severity score: pneumonia severity index and
CRB-65.
1740 F.W. Arnold et al.variables increased the predictive accuracy (AUC value) of
the PSI risk class for clinical stability within seven days from
0.638 to 0.658 (0.631, 0.682), and also increased the AUC
value of the CRB-65 from 0.647 to 0.653 (0.630, 0.684). The
additional process of care factors resulted in only marginal
improvement without changing clinical significance for
predicting time to clinical stability.
Discussion
The CRB-65 has been shown to have an association with
mortality and, to a lesser degree, with LOS, but never with
time to clinical stability until now. With that relationship
established, the score’s ability to predict time to clinical
stability was compared to the PSI, and found to be equiv-
alent. Neither score performed outstandingly well with AUC
values of approximately 0.6 for predicting which patients
would reach clinical stability within seven days. The
present study more broadly validates the PSI and CRB-65
scores. It showed that two pneumonia specific mortality
models used to quantify severity at the time of patient
presentation are also both associated to an equivalent
degree with a non-mortal downstream patient outcome;
time to clinical stability.
Table 5 Area under the ROC curve (AUC) for outcomes among hospitalized patients with community-acquired pneumonia for
the pneumonia severity index (PSI), PSI risk class and the CRB-65 score.
Outcome PSI PSI-RC CRB-65 PSI-RC e CRB-65
AUC 95% CI AUC 95% CI AUC 95% CI Difference 95% CI
TCS within 7 days 0.652 (0.627, 0.674) 0.638 (0.613, 0.660) 0.647 (0.619, 0.670) 0.009 (0.030, 0.010)
Discharge within 14 days 0.659 (0.633, 0.685) 0.651 (0.625, 0.674) 0.626 (0.600, 0.655) 0.025 (0.001, 0.049)
In-hospital 28-day 0.756 (0.722, 0.784) 0.738 (0.712, 0.765) 0.69 (0.651, 0.720) 0.049 (0.020, 0.082)
Mortality
CI, Confidence Interval; ROC, Receiver-Operating Characteristic curve; TCS, Time to Clinical Stability.
Pneumonia score predictive accuracy for time to stability 1741A longer LOS and higher mortality were associated with
incrementally higher PSI and CRB-65 scores as they were in
previous studies.7e10,14,26,27 In the present study, as else-
where,26,28 the PSI was statistically better at predicting
both LOS and mortality when compared to the CRB-65.
The present study revealed that the PSI and CRB-65,
although adequate and generally comparable, are not ideal
severity scores. Analyzing the two scores with additional
information regarding processes of care improved their
predictive accuracy by only a slight margin. The tools lack
perfect sensitivity and specificity as summarized in their
ROC curves. When plotting the ROC curves for LOS and
mortality, an ideal score would rise vertically and then turn
90 to finish as a horizontal line. As seen in both Figs. 3 and
4, neither score approached the model curve form. The fair
predictive accuracy of the scores for time to clinical
stability was not unexpected because they were originally
designed to predict mortality.
There are two implications of finding that the PSI and
CRB-65 scores predict time to clinical stability equiva-
lently: clinical practice and research. Physicians in the
hospital emergency department may use either score to
assist with a disposition decision. The place of patient careFigure 3 ROC curves for hospitalized patients with commu-
nity-acquired pneumonia being discharged within 14 days for
each severity score: pneumonia severity index and CRB-65.(e.g., ICU, ward, home) is an important implication of
correctly predicting risk at admission. In the clinical
setting, ease of use may be emphasized as a quality so that
such a tool (i.e., CRB-65) may be readily adopted.28 For
this reason, it has been recommended that validation
studies for severity scores be limited to data that is only
available in real time.27 The strength of a severity score,
however, is clinical research, not clinical practice, so
a tool may be practical without being necessarily easy to
use. A tool that can stratify populations and normalize
variables, such as antimicrobial regimens and co-morbid
illnesses, most accurately is preferred. At present, the PSI
and CRB-65 perform equivalently for this research purpose,
which provides the basis for evidence-based clinical
practice.
Regarding the context of other studies, certain longi-
tudinal, observational studies of hospitalized patients
with CAP comparatively had approximately 36% of patients
with combination therapy (b-lactam plus either a macro-
lide or a fluoroquinolone) and 50% with monotherapy (b-
lactam alone, or fluoroquinolone alone).12,29 Using these
definitions of mono and combination therapy, the present
study had 21% patients with monotherapy and 36% withFigure 4 ROC curves for hospitalized patients with commu-
nity-acquired pneumonia dying within 28 days for each severity
score: pneumonia severity index and CRB-65.
1742 F.W. Arnold et al.combination therapy. Mortality rates in other patients
with risk classes I, II and III were 0.4%, 0.7% and 2.8%,
respectively.5 Mortality rates in other patients with CRB-
65 scores 0, 1 and 2 were 1.2%, 5.3% and 12.2%,
respectively.10
The present study also had several limitations.
Although the overall mortality (w10%) was similar to
related studies, the mortality for patients with lower risk
classes and CRB-65 scores was higher. One explanation is
that the mortality of non-US patients with a low risk class
was elevated (risk class I 4.6% vs 0.7%). There is also the
possibility that low risk class patients had factors not
captured by either score, such as hypoxia or sepsis.30
When evaluating CRB-65, we did not use an objective
mechanism to evaluate “confusion”, such as the Abbre-
viated Mental Test Score, but rather subjective informa-
tion documented in the medical record.6 Another
limitation was the sample selection. All of the patients
were admitted through the Emergency Department, and
thus more likely to be severely ill and aged. In contrast,
the PSI and CRB-65 were created for a more ambulatory
population to determine hospital admission status. So, the
overall predictive accuracy of our study population, with
a mean PSI risk class of 3.3, matched the lower predictive
accuracy for mortality of the population found by Man et
al.27 with a mean PSI risk class of 3.5, and was in contrast
to the higher accuracy of two other study populations with
mean PSI risk classes of 2.7 each.14,26 Although, a large
number of patients were included, only 16 patients had
a CRB-65 score of 4.
The present study was strengthened by several factors.
The results reproduced the well-known relationships
between the PSI and CRB-65 severity scores with
LOS,14,15,27 and with mortality.7e10,26 Robust statistics
developed for time-to-event data, not used in previous
studies comparing pneumonia severity scores, were used in
the present study.22 The findings are more generalizable
because the present study was international, large, and
used lenient inclusion criteria which facilitated including
patients with multiple medical comorbidities in the obser-
vational review.
Overall, the PSI and CRB-65 were each significantly
associated with time to clinical stability. However, the
predictive accuracy of each score for time to clinical
stability leaves room for improvement, and research to
create a new score or to modify existing scores is encour-
aged. This work augments what is already known about
severity adjustment from the perspective of CAP research
by providing evidence to use either the PSI or CRB-65 when
analyzing time to clinical stability.Conflict of interest statement
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